A Prescription Drug Affordability Board (PDAB) is an independent body with the authority to evaluate high-cost drugs and set Upper Payment Limits (UPLs) on what Illinoisans will pay. This is similar to existing state practices for utilities and insurance premiums. UPLs apply to the entire supply chain, ensuring lower costs benefit consumers.

**A Prescription Drug Affordability Board (PDAB)**

- Five Member Board
- Stakeholder Council
- Full-Time Staff

**Evaluate High-Cost Drugs**
- New drugs: $60,000+
- Brand name drugs with $3,000+ increase
- Any drugs that pose affordability challenges

**Affects Entire Supply Chain**
- Manufacturers
- Wholesalers & PBMs
- Insurers & Pharmacies

**Upper Payment Limits**
- Set fair, affordable prices
- Consider barriers to access
- Apply to all purchasers and payer reimbursements

**Impact on Illinoisans**

- 28% of Illinoisans either have not filled prescriptions or rationed their medication due to cost
- 54% of Illinoisans are worried about affording their prescription medication
- 86% of Illinoisans are supportive of establishing a PDAB
- 1/3 of premium costs are due to high-cost prescription drugs

*2020 Healthcare Value Hub Poll

**Drugs don’t work if people can’t afford them.**
# Colorado PDAB Reviewed Drugs

<table>
<thead>
<tr>
<th>Reviewed Drug</th>
<th>Condition Treated</th>
<th>Patient Count</th>
<th>5-Year WAC Change</th>
<th>Patient OOP Cost</th>
<th>Total Paid in 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enbrel*</td>
<td>Rheumatoid Arthritis</td>
<td>1,707</td>
<td>36.24%</td>
<td>$2,812</td>
<td>$72,504,276</td>
</tr>
<tr>
<td>Genvoya</td>
<td>HIV</td>
<td>940</td>
<td>28.84%</td>
<td>$1,293</td>
<td>$27,344,595</td>
</tr>
<tr>
<td>Cosentyx</td>
<td>Psoriatic Arthritis/Plaque Psoriasis</td>
<td>456</td>
<td>46.94%</td>
<td>$2,168</td>
<td>$17,954,496</td>
</tr>
<tr>
<td>Stelara*</td>
<td>Psoriatic Arthritis/Crohn’s Disease/Ulcerative Colitis</td>
<td>414</td>
<td>23.87%</td>
<td>$1,399</td>
<td>$45,794,896</td>
</tr>
</tbody>
</table>

*Enbrel and Stelara are also on Medicare’s list of the first 10 drugs to be negotiated. Our model would allow for Upper Payment Limits to be tied directly to the federally negotiated drug prices.

## How PDAB Complements Medicare Drug Price Negotiations

Our PDAB model includes a component that leverages federal Medicare negotiations by adopting Maximum Fair Prices (MFPs) set by Medicare as upper payment limits (UPLs). This extends the benefits of drug price negotiations to the 62% of Illinoisans not on Medicare, expanding as Medicare negotiates more drug prices in future years.